Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06569342
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Botulinum Neurotoxin Type A BoNT-A in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder OAB
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Botulinum Neurotoxin Type A BoNT-A in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder OAB a Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A non-intervention cohort study on the use of Botulinum Neurotoxin Type A BoNT-A in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder OAB Primary endpoint was the reduction of urinary incontinence
Detailed Description:
The investigators wanted to cunduct an analysis of children with urinary incontinence who received intradetrusor injection of BoNT-A in the period 01012016 to 31122020 at their centre All patients were refractory to standard urotherapy anticholinergics mirabegron and combination of treatments Patients with neurogenic bladder were excluded
Primary endpoints were the effect on the frequency of urinary incontinence episodes Secondary endpoints included urodynamic parameters and uroflow characteristics in relation to side effects and response to treatment
Primary endpoints were the effect on the frequency of urinary incontinence episodes Secondary endpoints included urodynamic parameters and uroflow characteristics in relation to side effects and response to treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None